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Background/aim: The present study aimed to examine whether the combination of neoadjuvant volumetric modulated arc radiotherapy
(VMAT) using simultaneous integrated boost (SIB-VMAT) techniques and chemotherapy with capecitabine is associated with better clinical
and dosimetric outcomes compared to the standard treatment.
Materials and methods: The study included 59 patients with cT2–T4 rectal cancer. In the standard arm, patients (n = 37) were treated
preoperatively with image-guided VMAT plus capecitabine. In the SIB arm, patients (n = 22) were treated with the SIB-VMAT technique
plus capecitabine. All patients underwent radical surgical resection after neoadjuvant radiochemotherapy.
Results: In the standard arm, cT0N0 was reached in 12 patients (32.4%), primary tumor clinical downstaging was observed in 22 patients
(59.5%), and disease stability was achieved in 3 patients (8.1%). In the SIB arm, cT0N0 was reached in 15 patients (68.2%), primary tumor
clinical downstaging was observed in 6 patients (27.3%), and disease stability was achieved in 1 patient (4.5%) (P = 0.028). Complete
pathological response was observed in 11 patients (29.7%) in the standard arm and in 13 patients (59.1%) in the SIB arm (P = 0.026). In the
SIB arm mild diarrhea appeared in 59.1%, moderate in 40.9%, and severe in 0% of the cases. In the standard arm mild, moderate, and severe
diarrhea rates were in 54.1%, 43.2%, and 2.7%, respectively. In the SIB arm mild, moderate, and severe cystitis appeared in 63.6%, 22.7%,
and 13.6%, while in the standard group mild cystitis developed in 67.6%, moderate in 24.3%, and severe in 8.1%. Mild, moderate, and severe
radiation dermatitis rates were 45.5%, 45.5%, and 9.1% in the SIB group and 40.5%, 48.6%, and 10.8% in the standard group, respectively.
Conclusion: The SIB-VMAT technique is effective and safe for irradiating locally advanced rectal cancer. Its effectiveness is expressed in
higher clinical and pathological complete response rates and safety with the same rates of acute toxicity.
Key words: Rectal cancer, chemoradiotherapy, neoadjuvant, boost

1. Introduction
Locally advanced rectal cancer (LARC) includes cancers that
are extended through the rectal wall and/or have regional
lymph nodes involved. Treatment of LARC is associated
with great difficulties. Surgery, especially total mesorectal
excision (TME), is the most important treatment modality,
and in the case of margin-negative resections there is a high
chance of cure. However, a multidisciplinary approach
including preoperative chemoradiotherapy (CRT) may
offer long-term, recurrence-free survival [1].
In the case of LARC, preoperative CRT remains the
gold standard of treatment [2]. However, patients treated

with abdominoperineal resection may also receive CRT.
Many trials have demonstrated the benefits of preoperative
CRT with improved compliance, reduced toxicity, and
increased local control [3].
There have been improvements in treatment regimens.
Radical pelvic radiotherapy (RT) of up to 60 Gy is
associated with severe acute and late toxicities such as
diarrhea, cystitis, perineal dermatitis, genitourinary
dysfunction, and sacral fractures. Lower doses of 40–50
Gy provide good tumor response with acceptable levels
of toxicity. For this reason, 45–50 Gy in 25–28 fractions
has become established as the standard treatment scheme
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[4]. Hyperfractionation with acceleration or simultaneous
integrated boost (SIB) techniques has also been considered
[5,6].
At present for LARC, preoperative CRT followed by
surgery is preferred as the best treatment option. The
RT field for LARC is recommended to encompass the
primary tumor, entire mesorectum, presacral space, and
regional lymph nodes [7–10]. There are several clinical
trials of preoperative CRT for LARC using SIB-volumetric
modulated arc radiotherapy (VMAT), reporting good
oncologic outcomes with the same toxicities [11,12].
Based on these clinical data, we applied SIB-VMAT for
preoperative CRT in LARC. The aim of using preoperative
concurrent chemotherapy and VMAT-RT intensified with
SIB dose escalation was to evaluate the resectability and
pathological response in early clinical outcomes.

Table 1. Stage distribution between two groups.

2. Materials and methods
2.1. Patients’ characteristics
From February 2015 to March 2018, 37 patients with
cT2–T4 rectal cancer were treated preoperatively with IGVMAT-45 Gy in 25 fractions and an additional boost of
5.4 Gy in 3 fractions, plus capecitabine at 825 mg/m2 twice
daily. From September 2016 to April 2018, 22 patients with
cT2–T4 rectal cancer were treated with the SIB technique,
with 46 Gy for the elective volume and 57.5 Gy as a boost
to the rectal tumor in 23 fractions, plus capecitabine at
825 mg/m2 twice daily. Patients were included if they did
not have any comorbidities, contraindications for radical
surgery, or distant metastases, and also if the tumor
histopathology was adenocarcinoma.
The median age was 59 years (range: 36 to 84), and of
the 59 patients, 33 were male (55.9%) and 26 were female
(44.1%). None of them had evidence of distant metastasis
(M0). Rectal cancer stage ranged from stage I (T2) to
stage III, but most of the patients (72.9%) had stage III
rectal cancer (Table 1). The histopathology of all patients
(n = 59) was adenocarcinoma. The distribution of tumor
differentiation grade (G1, G2, G3) is shown in Table 2.
This study was approved by the institutional ethical
committee. All participants provided informed consent.
The study was conducted according to the Declaration
of Helsinki’s “Ethical Principles for Medical Research
Involving Human Subjects.”
2.2. Simulation technique
All patients were immobilized and treated in the supine
position. A supine set-up was associated with more
stability and was comfortable for the patient. During the
simulation procedure, special marks were painted on the
skin, which acted as a target for laser beams. These helped
to position the patient’s body for treatment. Simulation
was performed with a Siemens Somatom AS CT with
slice thickness of 3 mm and was aimed to achieve stable

conditions of bladder and rectal filling. This kept the small
bowel from migrating into the pelvis and reduced small
bowel toxicity.
2.3. Contouring
Target volumes and organs at risk (OAR) were delineated
on a SomaVision 13.7 (Varian Medical Systems). The gross
tumor volume (GTV) was determined by a combination
of findings from physical examination, endoscopy, CT,
MRI, and/or PET-CT. The primary clinical target volume
(CTV) included GTV plus pararectal area. Primary PTV
included CTVp plus 5 mm. The CTV node included the
internal iliac, presacral, and perirectal nodal groups along
with the external iliac nodal region (if lesions extended into
gynecologic/genitourinary structures or positive external
iliac lymph nodes) and the inguinal nodal region (if lesions
extended to the anal verge, perianal skin, or positive
inguinal nodes). The PTV node was generated with a
5-mm symmetrical margin around the CTV. The small
bowel, bladder, and femoral heads were defined as OAR.
2.4. Plan evaluation and radiotherapy procedure
All patients were treated with VMAT technique using the
TrueBeam linac system with 6 MV photons and Millennium
MLC (120 leaves) (Varian Medical Systems, Palo Alto, CA,
USA). Patients were checked daily using CBCT images and
were accepted for treatment if the relative variations of the
organs between the images were within 3 mm along the
three spatial directions.
All VMAT plans were with 2 arcs. The first arc was
clockwise with start and stop angles at 181° and 179°, while
the second one was anticlockwise with reversed start and
stop angles. The collimator angle was set to 10° and 350°.
All RapidArc (RA) plans were generated using 6
MV photon beams and modulated with 120 multileaf
collimators from a linear accelerator (TrueBeam v.2.5;
Varian Medical Systems). Optimizations and dose
calculations were performed with the Eclipse treatment

Treatment group

I
Stage

II
III

Total

Standard

SIB

n

2

2

%

5.4%

9.1%

n

5

7

%

13.5%

31.8%

n

30

13

%

81.1%

59.1%

n

37

22

%

100.0%

100.0%
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Table 2. Distribution of tumor differentiation grade within
treatment groups.
Treatment group

G1
Grade

G2
G3

Total

Standard

SIB

n

11

9

%

29.7%

40.9%

n

20

12

%

54.1%

54.5%

n

6

1

%

16.2%

4.5%

n

37

22

%

100.0%

100.0%

G1 (Grade 1) - Well differentiated, G2 (Grade 2) - Moderately
differentiated,
G3 (Grade 3) - Poorly differentiated.

planning system (version 13.7). We used the PO 13.7
optimization module (photon optimizer) and analytical
anisotropic algorithm to carry out final dose calculation
with 2.5-mm grid resolution.
Plan evaluation was performed with dose-volume
histogram parameters for target structures as well as for
OAR. For target structures, with primary as well as node
PTVs, we were investigating V95% (volume of the target,
covered by 95% of the prescribed dose) and V100%,
D99% (dose to 99% of the treatment volume), and the
relative volume exceeding 107% of prescribed dose in
PTVp (V107%, i.e. V53.928 Gy). For the bladder we were
evaluating V40 Gy (relative volume of the bladder receiving
40 Gy) and Dmax (a point defined as 0.035 mL or less was
evaluated as Dmax), V50 Gy and V40 Gy for the small
bowel in absolute volume (mL), and V45 Gy for femoral
heads.
For assessing dose distribution in the healthy tissue,
we reported homogeneity and conformity indexes of the
plans. The conformality index for PTVp and PTV node was
defined as the volume enclosed by the 95% isodose, divided
by the target volume. The homogeneity index of the plans
for PTVp and PTV node was calculated as (D2% – D98%)
/ D50%. For healthy tissue, we also reported the volume of
the body minus PTV receiving low doses (V5, V10, and
V20 Gy) [13,14].
The plans were optimized to meet the following
criteria: bladder volume, receiving 40 Gy less than 50%
and no volume should receive 60 Gy; small bowel volume,
receiving 50 Gy less than 20 mL and the volume receiving
40 Gy less than 100 mL; femoral head volumes receiving 45
Gy less than 25%.
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2.5. MRI and surgery
Pelvic MRI was performed after 6 weeks and surgery
was performed 8 weeks after completion of preoperative
treatment. Tumor size reduction on MRI after 6 weeks
was the primary endpoint. The secondary endpoint was
postoperative morphologic evaluation. Acute toxicities
were evaluated according to the Common Terminology
Criteria for Adverse Events (CTCAE), version 3.0, 2003.
2.6. Statistical analysis
Statistical analyses were performed using SPSS 16.0.
Descriptive statistics were demonstrated as mean
± standard deviations (SD) or median (minimum–
maximum) for continuous variables and as a percentage
(%) for nominal variables. The continuous variables were
compared by independent samples t-test. The chi-square
test or Fisher’s exact test was used to compare nominal
variables. P < 0.05 was considered statistically significant.
3. Results
All patients enrolled in both arms underwent radical
surgical resection. Tumor response was evaluated according
to the RECIST criteria. R0 resection was achieved in all
patients. In the standard arm, cT0N0 was reached in 12
patients (32.4%), primary tumor clinical downstaging was
observed in 22 patients (59.5%), and disease stability was
achieved in 3 patients (8.1%). In the SIB arm, cT0N0 was
reached in 15 patients (68.2%), primary tumor clinical
downstaging was observed in 6 patients (27.3%), and
disease stability was achieved in 1 patient (4.5%) (P =
0.028). Complete pathological response was observed in
11 patients (29.7%) in the standard arm and in 13 patients
(59.1%) in the SIB group (P = 0.026). Toxicity in both arms
was the same: gastrointestinal toxicities, skin toxicity, and
other genitourinary complications (Table 3).
For dosimetric parameters, we were investigating V95
(%), V100 (%), D99 (Gy), and V107 (%) for primary as
well as for node PTVs. We evaluated mean values for
each group and compared the data to each other. In the
SIB group, for primary PTV the mean value of V95 (%)
was 98.0400, of V100 (%) was 48.8800, of V107 (%) was
0.0164, and of D99 (Gy) was 54.2600. For nodal PTV, in
the same group, the mean value of V95 (%) was 99.3560,
of V100 (%) was 90.5000, of V107 (%) was 52.1200, and of
D99 (Gy) was 44.4400. In the standard group, for primary
PTV the mean value of V95 (%) was 99.6000, of V100 (%)
was 50.5600, of V107 (%) was 0.0025, and of D99 (Gy) was
48.5000, while for nodal PTV the mean value of V95 (%)
was 99.7800, of V100 (%) was 88.3000, of V107 (%) was
43.7400, and of D99 (Gy) was 43.5140.
For the bladder we were evaluating V40 (%) and Dmax
(Gy), a point defined as 0.035 mL or less, V50 Gy and V40
Gy for the small bowel in absolute volume (mL), and V45
(%) for the left and right femoral heads. In the SIB group,

JANKARASHVILI et al. / Turk J Med Sci
Table 3. Distribution of acute toxicities within treatment groups.
Treatment group

Diarrhea

Cystitis

Dermatitis

Standard (n = 37)

SIB (n = 22)

P-value

G1

20 (54.1%)

13 (59.1%)

0.706

G2

16 (43.2%)

9 (40.9%)

0.861

G3

1 (2.7%)

0 (0.0%)

0.437

G1

25 (67.6%)

14 (63.6%)

0.758

G2

9 (24.3%)

5 (22.7%)

0.889

G3

3 (8.1%)

3 (13.6%)

0.497

G1

15 (40.5%)

10 (45.5%)

0.712

G2

18 (48.6%)

10 (45.5%)

0.812

G3

4 (10.8%)

2 (9.1%)

0.833

Acute toxicities according to Common Terminology Criteria for
Adverse Events (CTCAE), version 3.0, 2003. G1 (Grade 1) - Mild
AE, G2 (Grade 2) - Moderate AE, G3 (Grade 3) - Severe AE.

for the bladder, mean values of V40 (%) and Dmax (Gy)
were 47.1760 and 59.1400, respectively. In the same group,
for the small bowel, the mean value of V50 (mL) was
19.6000 and V40 (mL) was 94.1600. For the left femoral
head, the mean value of V45 (%) was 9.9700, and for the
right femoral head V45 (%) was 7.4200. In the standard
group, for the bladder, mean values of V40 (%) and Dmax
(Gy) were 47.0740 and 51.2660, respectively. In the same
group, for the small bowel, the mean value of V50 (mL)
was 18.3320 and V40 (mL) was 90.6780, while for the left
femoral head the mean value of V45 (%) was 5.0140 and
for the right femoral head V45 (%) was 5.1140.
4. Discussion
This paper reports the advantages of the SIB-VMAT
technique for the treatment of LARC, which is expressed in
increased number of pathological complete response and
the same levels of acute toxicity. Recent studies have shown
that there is a relationship between dose escalation and
pathological response after treatment [15,16]. According to
some studies, there are high rates of pathological complete
response in those patients who receive radiotherapy with
high doses, such as 55–60 Gy [17]. Increased number
of complete responses will have a significant impact on
local recurrence-free and disease-free survival. In many
European centers, RT only was used as the neoadjuvant
treatment for LARC [18], but two randomized trials
have shown better local control rates when adding
chemotherapy to neoadjuvant RT [19,20]. Fluorouracil (5FU) and leucovorin improved complete response and local
recurrence rates, but an increase of acute toxicity was also

observed [21]. There are some new phase II trials in which
new chemotherapy regimens are being tested, such as oral
5-FU [22,23] or oxaliplatin [24] and irinotecan [25,26]
in combination with fluorouracil. Not only neoadjuvant
chemoradiation but also chemotherapy first following
chemoradiotherapy showed good response in case of
nonresectable rectal cancer [27]. Other modalities such
as intensity-modulated radiotherapy (IMRT) have shown
some advantages in cases of rectal cancer. First of all, it
is possible to deliver much more concave and uniform
dose distributions, which guarantee full conformation
to the horseshoe shape of the CTV. IMRT also gives us
the opportunity to use a simultaneously integrated boost
on GTV to achieve further tumor downstaging without
increasing acute toxicities [28]. These and other phase II
and III trials are ongoing, but until randomized phase III
trials demonstrate improved results, 5-FU-based CRT is
the gold standard for locally advanced and recurrent rectal
cancer patients [29].
Image-guided treatment delivery using kilo-voltage
cone beam computed tomography (kV CBCT), helped
to minimize interfraction set-up errors. This gave us the
possibility to minimize the set-up margin for targets.
Besides high-quality image guidance during treatment
delivery, a major advantage of the VMAT technique is
the significant reduction in treatment times and sparing
the surrounding normal structures. Patient compliance
to treatment has been significantly increased. In addition,
the time gained can be used to increase patient throughput
or to increase image guidance. The SIB-VMAT technique
also provides the delivery of higher doses only to the GTV,
while the CTV receives standard doses. This leads to better
downstaging, increases the number of R0 resections, and
provides better dosimetric outcome [30].
The results of this paper show that in rectal tumor
irradiation, conformal dose, lower doses to OAR, higher
doses to GTV, and faster delivery are achieved by VMAT
technique.
Future studies will show if the reduction of normal
tissue irradiation is associated with a reduced percentage
of late treatment-related toxicity. The regimen used in
this study allowed achievement of higher complete and
near-complete response rates in the SIB arm despite the
advanced stage of the disease, without increased risk
of radiation-induced severe acute toxicities. Although
longer follow-up is necessary to establish the efficacy of
neoadjuvant VMAT radiochemotherapy with SIB, several
conclusions are possible from these patients.
In
conclusion,
we
evaluated
SIB-VMAT
chemoradiotherapy efficacy in the treatment of LARC.
The clinical study revealed high efficiency and safety of the
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described method of treatment. Future studies and followup will show if the high rates of clinical and pathological
compete response is associated with a reduced percentage
of local recurrence and improvement of disease-free or
overall survival rates.
Our study has some limitations. The small number of
patients did not allow us to draw a definitive conclusion,
and the high rates of clinical and pathological complete
response still do not mean that these will have an impact
on oncological outcome. The follow-up period is too short
to assess the clinical value of the obtained results.

Future neoadjuvant trials also should focus on
obtaining tissue from primary tumors and enlarged lymph
nodes before and after treatment. With modern molecular
biology techniques, evaluation of gene expression and
chemotherapeutic resistance markers can be performed.
Correlation between resistance markers or other molecular
markers and the propensity of cells to metastasize can be
identified. Based on these molecular markers and their
high accuracy, it will become possible to identify patients
for whom neoadjuvant chemotherapy will have the most
benefit.
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